Supplementary Table 1: Sequences recovered from each of the GANNAG selections.

See attached excel file (Supplementary Table 1.xlsx) for the sequences of the 2 finger modules recovered from each binding site selection.

Supplementary Table 2: Recognition helix sequences (positions 5 & 6 of Finger 1 and -1, 1 & 2 of Finger 2) of 16 two-finger modules that preferentially recognize each of the GANNAG target sites. Light blue background indicates modules where the indicated dinucleotide junction is not the most preferred sequence.

5'

	Α	С	G	Т	3'
Α	RV QLI	KV QKP	KR QRN	RT QRS	
С	KT DPA	KR DPS	KR DKS	RT DHS	
G	KV RKG	KQ RNS	VR RFD	RT RSD	
т	KD ARG	RV HSS	KR LKY	QS FRT	

Supplementary Table 3. Sequences of the modularly-assembled and stitched ZFAs utilized in ZFNs in this study. (See attached file Supplementary Table 3.xlsx)

Supplementary Table 4: Comparison of modules used in ZFNs from the CoDA¹ study and our recent two finger module archives.

	CoDA ¹	gANNHg ²
Number of ZFNs assayed	39	18
Number of ZFNs active (>1%)	20	13
Percentage of GNN modules	99%	51%
Number of ZFNs with non-GNN fingers		
(number of active ZFNs)	2 (1)	18 (13)

1. Sander et. al., Nat. Methods 8, 67-69, 2011

2. ZFNs in this study and Gupta *et. al.*, *Nat. Methods* **9**, 588-90, 2012

Supplementary Table 5:

	Gupta 1/2FM	w/stitching
Archive Reference	A	В
Number of Unique ZFN sites in zebrafish protein- coding exons (25090 unique genes Zv9.64)	608,081	754,923
Fraction of zebrafish protein-coding genes containing ZFN site	95.0%	98.0%
Average density of ZFN sites (# bp/site)	132	109

A = Gupta, A. et al. *Nat. Methods* **9**, 588-90, 2012 & Zhu, C. et al. *Development* **138**, 4555, 2011.

B = Modules in Gupta 1/2FM archive and the new fingers and stitching method in this manuscript

Supplementary Figure 1. Recognition motifs for 77 GANNAG two-finger modules characterized in the B1H system. The recognition motif for each two-finger module is displayed as a Sequence Logo. The identity of the specificity determinants at the randomized recognition positions (Finger 1 positions 5 and 6, and Finger 2 positions -1, 1 and 2) in the characterized module are displayed above each recovered recognition motif.

Supplementary Figure 2. T7EI analysis of lesions in zebrafish targets for modularly-assembled ZFNs (*IRS2, met* and *sim1a*). Schematic representation of the 3 pairs of ZFNs targeting *IRS2, met* and *sim1a* are shown above each gel. Only the six finger constructs are shown. Finger number was reduced by progressively removing fingers from the N-terminus of the constructs. The positions of two-finger modules (GANNAG) described herein or fingers from other archives (GRNNCG (50) and single fingers (41)) within these ZFAs are indicated as in Figure 4, as is the position of the THPRAPIPKP linker that allows a single base pair to be skipped between intervening modules (65). T7EI digestion of PCR products spanning the genomic target site for normal embryos are shown. Cleavage products of the appropriate size for ZFN-induced lesions are indicated by red dots.

Supplementary Figure 3. B1H DNA-binding specificity for *abcc8* and *BRCA1* ZFAs. Sequence logos for each ZFA are shown with the dinucleotide junctions at the stitched interfaces boxed. The desired recognition sequence is shown to

the left of the logo with the dinucleotide junctions at the stitched interfaces underlined and the Adenines representing positions of two-finger module splice sites in bold. The recognition helices of the fingers are shown to the right of the logos with the C-terminal finger listed at the bottom. Stitched fingers are boxed in red.

Supplementary Figure 4. Top) Dose response curve of the *hebp2* ZFNs in zebrafish embryos. Morphology of embryos was assayed at 24 hpf (24). Bottom) Lesion frequency was assessed by T7EI sensitivity of a PCR product spanning the genomic target site (39,63). Lesion frequency was determined by ImageJ analysis of the uncleaved and cleaved DNA bands, where the black dot indicates the position of the cleaved band on the gel.

Supplementary Figure 5. Top) Dose response curve of the *abcc8* ZFNs in zebrafish embryos. Morphology of embryos was assayed at 24 hpf (24). Bottom) Lesion frequency was assessed by T7EI sensitivity of a PCR product spanning the genomic target site (39,63). Lesion frequency was determined by ImageJ analysis of the uncleaved and cleaved DNA bands, where the black dot indicates the position of the cleaved band on the gel.

Supplementary Figure 6. Top) Dose response curve of the *col17a1a* ZFNs in zebrafish embryos. Morphology of embryos was assayed at 24 hpf (24).

Bottom) Lesion frequency was assessed by Hpy166II resistance of a PCR product spanning the genomic target site. Lesion frequency was determined by ImageJ analysis of the uncleaved and cleaved DNA bands, where the red dot indicates the position of the uncleaved band on the gel.

Supplementary Figure 7. Lesion analysis for the *BRCA1* ZFNs in 293T cells. Lesion frequency was assessed by T7EI sensitivity of a PCR product spanning the genomic target site (39,63). Lesion frequency was determined by ImageJ analysis of the uncleaved and cleaved DNA bands, where the black dot indicates the position of the cleaved band on the gel.

Supplementary Figure 8. Lesion sequences recovered from zebrafish ZFN loci. Wild-type sequences are shown at the top of each set of sequence for each ZFN. Sequences with lesions recovered from our LacZ reporter system are shown below with the type of lesion indicated to the right of the sequence.

Supplementary Figure 1.













AT-SRS





GR-TVH

KA–LSA





KA-QRS



IV-VRS



KA-RNF







KA-RRY



KA-YKS



KA-YKT





KD-DRS



KD-QRG



KL-CRS







KQ-RRN

KN-DPA

KQ-DPA



KR-DKS



KQ-RNS



KR-DPS





KQ-RSS



KR-LKY



KR-LRQ







KR-LSY



KR–QAG



KR-QRG

KR–QAY





KR-QRC

KS-RSD



KR–QRN



KV-QKP



KV-RKG





LE-LKG



LR-DPT





MD-ARG





LR-TAY



LV-QSG



MS-VKQ



NK-DPS





QV-QRS



QA-FGG

RL-SRS





QS-FRT



QV-HSS



RR-**TRY**



RS-AKS









RT-DRS



RT-QRS



RT-RID







RV-HSS





VR-RFD



RV-QRG



Zif268





VI-QSS



VR-CGS



Supplementary Figure 2.











2.8%

3.6%

100 bp

hebp2 ATTGATACTTTTCagggtGATGACTATGAAG

Supplementary Figure 5.



abcc8 CGGCTTCTCtgtggACAGATAATGCA



11.4% 11.1% 9.2% 15.2%

Supplementary Figure 7.

BRCA1 CTGTGGTTGGTCagaaaGATAAGCCAGTT



2.7%

Supplementary Figure 8.

hebp2	GAA Reference sequence GAATTGATACTTTTCAGGGTGATGACTATGAAGTCCG-4GAATTGATACTTTTCAGATGACTATGAAGTCCG-4GAATTGATACTTTTCATGACTATGAAGTCCG-6GAATTGATACTTTTCTATGACTATGAAGTCCG-11GAATTGATACTTTTCTATGACTATGAAGTCCG-6, +1GAATTGATACTTTGTGGATGACTATGAAGTCCG-8,+3GAATTGATACTTTTCAGGTACTATGAAGTCCG-6, +1GAATTGATACTTT-GATACTTTGATGACTATGAAGTCCG-6, +1GAATTGATACTTT-GATACTTTGATGACTATGAAGTCCG-6, +1GAATTGATACTTT-GATACTTTGATGACTATGAAGTCCG-6, +1GAATTGATACTTTTCACTATGTGAAAACTATGAAGTCCG-6, +7GAATTGATACTTTTCACTATGTGAAAACTATGAAGTCCG-8, +10
IRS2	CAGGCCATCCAACTTTTCACAGAACAAGACTAGCAGAGACATGTTGGATReference sequenceCAGGCCATCCAACTTTTCACACAGGCCATCCAACTTTTCACAAGACTAGCAGAGACATGTTGGAT-4CAGGCCATCCAACTTTTCACAGCTAGCAGAGACATGTTGGAT-7-7CAGGCCATCCAACTTTTCACAGCTAGCAGAGACATGTTGGAT-7-7CAGGCCATCCAACTTTTCACAGCTAGCAGAGACATGTTGGAT-9-10CAGGCCATCCAACTTTTCACAGCAGAGACATGTTGGAT-10-11CAGGCCATCCAACTTTTCACAGCAGAGACTAGCAGAGACATGTTGGAT-11-11CAGGCCATCCAACTTTTCACAGCAGAGACTAGCAGAGACATGTTGGAT-10, +3-10, +3CAGGCCATCCAACTTTTCACAGCAGACTAGCAGAGACTAGCAGAGACATGTTGGAT-10, +3-6, +14CAGGCCATCCAACTTTTCACAGAGAAAAAGCTTTTCACAGAGAGACTAGCAGAGACATGTTGGAT-14, +23-14, +23
coll7a1a	CACGTCCTGCTGGTCACCTCGACTATCAGGTATCAReference sequenceCAGGTCCTGCTGGTGGACTATCAGGTATCA-6CAGGTCCTGCTGGTCCTATCAGGTATCA-8CAGGTCCTGCTGGTCCTGGATAGGACTATCAGGTATCA-9CAGGTCCTGCTGGTCCTGGATAGGACTATCAGGTATCA-4, +6CAGGTCCTGCTGGTCCACCT_ACCTGGACTATCAGGTATCA+4CAGGTCCTATCAGGACTATCAGGACTATCAGGTATCA-12, +13
abcc8	TAACGGCTTCTCCGTGCACAGATAATGCACTGReference sequenceTAACGGCTTCTCCGTAACGGACAGATAATGCACTG+3TAACGGCTTCGTGGACAGATAATGCACTG-4TAACGGCTTCTCCAGATAATGCACTG-6TAACGGCTTCTCAGATAATGCACTG-7TAACGGCTTGATAATGCACTG-1
simla	AGACCCTAATCCGAGCCACACAGCAGATGATCAAAGAGGAGGAAA Reference sequence AGACCCTAATCCGAGCCACAGCAGATGATCAAAGAGGAGGAAA -2 AGACCCTAATCCGAGCCACAGATGATCAAAGAGGAGGAAA -5
met	CTCCTCCTGCTCCTGATC GCTGTGTTTGTTTGGATCAAGAGAAA Reference sequence CTCCTCCTGCTCCTGATG -6